June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Mid-term efficacy and safety of adalimumab in refractory pediatric uveitis : a retrospective monocentric study
Author Affiliations & Notes
  • Benjamin Penaud
    1Ophthalmology department, Pitié-Salpêtrière hospital, Paris, France
  • Emmanuelle Champion
    1Ophthalmology department, Pitié-Salpêtrière hospital, Paris, France
  • Christine Fardeau
    1Ophthalmology department, Pitié-Salpêtrière hospital, Paris, France
  • Phuc Le Hoang
    1Ophthalmology department, Pitié-Salpêtrière hospital, Paris, France
  • Pierre Quartier
    Pediatric rheumatology, Necker Hospital, Paris, France
  • Bahram Bodaghi
    1Ophthalmology department, Pitié-Salpêtrière hospital, Paris, France
  • Footnotes
    Commercial Relationships Benjamin Penaud, None; Emmanuelle Champion, None; Christine Fardeau, None; Phuc Le Hoang, allergan (C), bausch Lomb (R), santen (C); Pierre Quartier, Abbott (F); Bahram Bodaghi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2545. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Benjamin Penaud, Emmanuelle Champion, Christine Fardeau, Phuc Le Hoang, Pierre Quartier, Bahram Bodaghi; Mid-term efficacy and safety of adalimumab in refractory pediatric uveitis : a retrospective monocentric study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2545.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have previously reported the short-term results of anti-TNF therapy in the pediatric population with severe uveitis. Our aim is to evaluate the mid-term efficacy and safety of adalimumab in the same population.

Methods: We retrospectively analysed 15 children with severe uveitis, who were treated with adalimumab (20 or 40-mg, every two weeks) when the previous immunosuppressive therapy has been ineffective. It consisted of systemic corticosteroids (n=15), methotrexate (n=15), azathioprine (n=5), mycophenolate mofetil (n=1), infliximab (n=6), etanercept (n=6), interferon-alpla (n=1). The etiology of uveitis was juvenile idiopathic arthritis (n = 11), sarcoidosis (n = 1), spondyloarthropathy (n = 1), idiopathic or unknown (n = 2). Primary outcome was to assess laser flare photometry values after adalimumab therapy compared with baseline. Clinical features (Standardization of Uveitis Nomenclature criteria, macular edema and papillitis), oral prednisone threshold, visual acuity, side effects and complications of treatment were also considered.

Results: Median age was 13.1 years (range 6-20.8) and sex ratio (F/M) was 3. Median duration before adalimumab therapy was 82.6 months (range 16-262). The mean follow-up was 35.5 months (range 4-63) and the final median laser flare photometry value was significantly reduced from 149.5 ph/ms (range 24-335) to 85.4 ph/ms (range 4-224) p<0.005. Median oral prednisone decreased from 10.3 mg/day (range 0-30) to 3.2 mg/day (range 0-15) p<0.05. Uveitis was controlled in 11 cases (73.3%). Relapses occurred in one case (6.7%), adalimumab was ineffective in one case (6.7%) and was stopped in a patient who had excellent control of inflammation. Three children (20%) discontinued treatment due to severe side effects : one due to intolerance with an allergic reaction, one due to neurologic side-effects (optic neuropathy, polyneuropathy), one because of behavioral disorders.

Conclusions: Adalimumab appears to be an effective and well tolerated treatment for refractory pediatric uveitis, with prolonged control of inflammation over several years, even after failure of other anti-TNF alpha agents. A prospective randomized double blind study is currently ongoing in order to confirm these retrospective results.

Keywords: 746 uveitis-clinical/animal model • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 555 immunomodulation/immunoregulation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×